NCT05166421 - Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants | Biotech Hunter

Enrollment

224

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

July 19, 2023

Study Completion Date

July 19, 2023

Conditions

Corona Virus Disease

Interventions

BIOLOGICAL

AZD7442

AZD7442 will be administered via IM route.

BIOLOGICAL

AZD8895 (clonal cell line material)

AZD8895 will be administered via IM route.

BIOLOGICAL

AZD1061 (clonal cell line material)

AZD1061 will be administered via IM route.

BIOLOGICAL

AZD8895 (cell pool material)

AZD8895 will be administered via IM route.

BIOLOGICAL

AZD1061 (cell pool material)

AZD1061 will be administered via IM route.

Trial Locations (14)

29379

Research Site, Union

32132

Research Site, Edgewater

33462

Research Site, Lake Worth

35055

Research Site, Cullman

36207

Research Site, Anniston

77058

Research Site, Houston

83642

Research Site, Meridian

85260

Research Site, Scottsdale

90806

Research Site, Long Beach

91606

Research Site, North Hollywood

91911

Research Site, Chula Vista

91942

Research Site, La Mesa

320919

Research Site, Orlando

08009

Research Site, Berlin